An Open-Label Study of Aripiprazole in Children with a Bipolar Disorder

作者：Findling Robert L^*; McNamara Nora K; Youngstrom Eric A; Stan**rey Robert J; Frazier Thomas W; Lingler Jacqui; Otto Benjamin D; Demeter Christine A; Rowles Brieana M; Calabrese Joseph R

来源：Journal of Child and Adolescent Psychopharmacology, 2011, 21(4): 345-351.

DOI：10.1089/cap.2010.0102

Objective: The purpose of this open-label study was to describe the effectiveness of aripiprazole (APZ) in the treatment of children with bipolar disorders suffering from manic symptomatology.
Method: Symptomatic outpatients (Young Mania Rating Scale [YMRS] score >= 15) meeting strict, unmodified, Diagnostic and Statistical Manual of Mental Disorders, 4th edition, diagnostic symptom criteria for a bipolar disorder, ages 4-9 years, were eligible. Subjects were treated prospectively with flexible doses of APZ (maximum daily dose of 15 mg/day), for up to 16 weeks or until a priori response criteria were met. Outcome measures included the YMRS, Clinical Global Impressions Scale-Severity, Children's Global Assessment Scale (CGAS), and the Children's Depression Rating Scale-Revised (CDRS-R). A priori response criteria consisted of 3 of 4 consecutive weeks with (1) CDRS-R < 29; (2) YMRS < 10; and (3) CGAS > 50.
Results: Ninety-six children (62 males; mean age of 6.9 (SD = 1.7), received APZ for an average length of treatment of 12.5 (SD 3.9) weeks. Significant improvements in YMRS, CDRS-R, CGAS, and Clinical Global Impressions Scale-Severity scores (p < 0.001) were noted at the end of study participation. Sixty of the subjects (62.5%) met a priori response criteria at study's end. The most common side effects noted were stomachache, increased appetite, and headache. Two subjects were removed from the study due to side effects [epistaxis (n = 1); akathisia (n = 1)]. Subjects experienced an average weight gain of 2.4 (SD = 1.9) kg.
Conclusion: APZ may be effective in the acute treatment of symptoms of children with bipolar illnesses.

• 出版日期2011-8